The effect(s) of endogenously synthesized cholesterol (endoCHOL) on the endosomal system in mammalian cells has not been examined. Here, we treat Chinese hamster ovary cell lines with lovastatin (a HMG-CoA reductase inhibitor) and mevalonate (a precursor for isoprenoids) to block endoCHOL synthesis, then examine its effects on the fate of cholesterol liberated from low-density lipoprotein (LDL-CHOL). The results show that blocking endoCHOL synthesis for 2 h or longer does not impair the hydrolysis of cholesteryl esters, but partially impairs the transport of LDL-CHOL to the plasma membrane. Blocking endoCHOL synthesis for 2 h or longer also alters the localization patterns of the late endosomes/lysosomes and retards their motility, as monitored by timelapse microscopy. LDL-CHOL overcomes the effect of blocking endoCHOL synthesis on endosomal localization pattern and on endosomal motility. Overexpressing Rab9, a key late endosomal small GTPase, relieves the endosomal cholesterol accumulation in Niemann-Pick type C1 cells, but does not revert the reduced endosomal motility caused by blocking endoCHOL synthesis. Our results suggest that endoCHOL contributes to the cholesterol content of late endosomes and controls its motility, in a manner independent of NPC1. These results also support the concept that endosomal motility plays an important role in controlling cholesterol trafficking activities.
INTRODUCTION
Cholesterol is an important lipid molecule present ubiquitously in mammalian cells. It plays important structural and functional roles in cell membranes (1) . In specialized cells such as steroidogenic cells or hepatocytes, cholesterol serves as an obligatory precursor for steroid hormones and bile acids. Almost all mammalian cells receive exogenous cholesterol, mainly via the classic low-density lipoprotein (LDL) 1 receptor pathway: LDL binds to the LDL receptor and enters the cell interior by receptor-mediated endocytosis (2) . While present in the earlier endosomal compartment(s), most of the cholesteryl esters in LDL are hydrolyzed by the enzyme acid lipase (3); the free (unesterified) cholesterol liberated from cholesteryl ester then emerges in the late endosomes (4, 3) . The egress of cholesterol from the late endosomes requires the concerted actions of several proteins, including the Niemann-Pick type C1 (NPC1) and NPC2 proteins (reviewed in (5)); both NPC1 and NPC2 proteins directly bind cholesterol ((6, 7); reviewed in (8) ). Mutations in either NPC1 or NPC2 cause cholesterol (and other lipids) to be entrapped in the aberrant endosomes/lysosomes, and prevents it from being delivered to various destinations, including the plasma membranes (PM), transGolgi network (TGN), and the endoplasmic reticulum (ER), where cholesterol would normally be reesterified by the ER resident enzyme acylcoenzyme A:cholesterol acyltransferase 1 (ACAT1) (reviewed in (9, 5) ). In addition to the cells that contain NPC1 or NPC2 mutations, cells treated with U18666A (a hydrophobic amine (10) ), or cells that contain various other mutations (11, 12) can also accumulate cholesterol abnormally, and exhibit NPC-like phenotypes (reviewed in (8) ). Late endosomes exhibit long distance, bidirectional motility between the peripheral region and the perinuclear region of the cells (13) . In general, the motility of endosomal organelles depends on microtubules, various motor proteins and Rab proteins (reviewed in (14) ). Rab proteins are a family of small GTPases present in various endosomal organelles, and play important roles in membrane trafficking events (reviewed in (15) ). Recently, it was shown that in cells that display NPC-like phenotypes, cholesterol derived from LDL accumulates and blocks the dissociation of Rab7, a Rab protein mainly located in the late endosomes, from its regulator protein guanine nucleotide dissociation inhibitor (GDI), causing the Rab7 protein to be locked in an inactive state, and significantly diminishing the motility of the late endosomes (13) . This study links late endosomal motility with intracellular cholesterol trafficking activities. The accumulation of cholesterol in NPC cells also inhibits the function of Rab4, a different GTPase that is mainly located in the earlier endosomes (16) .
In addition to receiving cholesterol via LDL, essentially all mammalian cells also synthesize cholesterol endogenously (endoCHOL). The de novo biosynthesis of endoCHOL uses acetyl coenzyme A as the simple precursor, and involves many enzymatic reactions. The terminal stage of endoCHOL synthesis is at the ER (reviewed in (17) ). Once synthesized, the nascent endoCHOL is rapidly transported in an energy-dependent manner to the caveolae/lipid raft microdomain of the PM within 10 to 20 min (18) (19) (20) (21) . These processes do not require NPC1 (22) . At the PM, endoCHOL may recycle rapidly (within minutes) between the PM and the recycling endosomes (23) . Other fate(s) of the endoCHOL remains largely unclear. However, it is known that in mutant NPC1 cells, eight h or longer after its initial synthesis, certain portion of endoCHOL is significantly trapped within the late endosomes; the entrapment partially disables the recycling of endoCHOL from the late endosomes to the PM, and its movement to the ER for esterification by ACAT1 (24, 25) . Thus, similar to the LDL-CHOL, the post-PM intracellular trafficking of endoCHOL partially depends on NPC1. These results suggest that endoCHOL that traverses through the endocytic compartment may play important role(s) in controlling the function/properties of the late endosome(s). In the current manuscript, we used wild-type (WT) and various well-characterized mutant Chinese hamster ovary (CHO) cells as tools and investigated the role of endoCHOL in the endocytic pathway. We blocked endoCHOL synthesis by treating cells with lovastatin (also called mevinolin) and mevalonate. Lovastatin is the drug that blocks endoCHOL synthesis by inhibiting the key enzyme HMG-CoA reductase in the earlier part of the sterol biosynthesis pathway (26) . Mevalonate is the reaction product of HMGCoA reductase. It is an obligatory intermediate for all isoprenoids, including cholesterol, ubiquinone, dolichol, etc., that are all needed for cell growth and survival (reviewed in (27) ). When added to the culture medium, only a small amount of mevalonate can enter the cell interior; it cannot satisfy the lovastatin-treated cells' needs for sterol, but it enables them to synthesize various other mevalonate-derived, non-sterol metabolites necessary for cell growth. We examined the endocytic activities of the cells by monitoring the fate of cholesterol liberated from the low-density lipoprotein LDL (LDL-CHOL). Our results indicate that endoCHOL plays a significant role in maintaining the functions of the late endosomes.
EXPERIMENTAL PROCEDURES
Materials -Fetal bovine serum (FBS), 2-hydroxypropyl-β-cyclodextrin (CD), paraformaldehyde, and mevalonic acid (mevalonate) were from Sigma. The lipid-free FBS was prepared as described (28 4 cpm/µg protein was prepared according to published procedure (31) . DiI-LDL was prepared as previously described (32) . The NPC1-GFP expression plasmid was as previously described (33) . The Rab9-YFP expression plasmid was a gift of Dr. Yiannis Ioannou of Mount Sinai School of Medicine (34) .
Production of antibodies against hamster NPC1 (DM105) -The N-terminal portion of the hamster NPC1 protein (amino acid residues 35-172, approx. 34 kDa) was expressed as a fusion protein adduct with the bacterial protein GST. To produce the fusion protein, the primer sets used for PCR are as follows: forward primer, CGCGGATCCTTTGGAGATAAGAAGTACAA C (corresponding to BamHI restriction site and to the nucleotide sequence 103-123 of hamster NPC1; (38) ); reverse primer, CCGGAATTCGGCCTTCTCATTACTTGCAGG (corresponding to EcoRI restriction site and to the nucleotide sequence 498-516 of hamster NPC1). The resulting PCR product was digested with BamHI and EcoRI and ligated into the pGEX-4T1 vector (Pharmacia Biotech) that had been digested with BamHI and EcoRI, followed by gel purification. The fusion protein was expressed in E. coli and purified by SDS-PAGE, based on the procedure previously employed (29) . The purified protein in 0.2% SDS solution was sent to Cocalico Co. (Philadelphia, PA) to generate antisera in rabbits. The antisera were purified via GST-NPC1 fusion protein affinity column chromatography, and stored at 4 ˚C in 0.1 M Tris-glycine buffer, pH 7.0, under sterile condition.
Immunoblotting Analysis -Western blotting with anti-NPC1 polyclonal antibodies (DM105) was performed as follows: WT-CHO cells were solubilized in lysis buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Nonidet P-40, and Protease Inhibitors Cocktail (Sigma)) on ice for 30 min, followed by centrifugation at 13,000 rpm for 20 min at 4 ˚C. After adding (4 x) SDS-loading buffer with 0.1 M DTT to the solubilized cell lysate, the samples were kept on ice until the SDS-PAGE analysis. Treating the samples in SDS at 37 ˚C or 60 ˚C caused a large loss in NPC1 signal in Western blotting (result not shown). The primary antibodies used were the affinity-purified IgG against the GST-NPC1 protein, at 0.8 µg/ml, in TBS-0.3% Tween 20 buffer containing 1% skim milk. Western blotting with anti-NPC2 polyclonal antisera was performed essentially as described previously (7) . Results of Western blots were quantified by using the NIH image (version 1.63). To normalize the values, the mean pixel intensities obtained with anti-NPC1 or with anti-NPC2 were divided by those obtained with antibeta-actin.
Cell lines and procedures for cell culture work -WT CHO cells were originally from ATCC. 25RA cells were derived from the WT CHO cells; they are resistant to the cytotoxicity of 25-hydroxycholesterol (35) and contain a gain of function mutation in the sterol regulatory element binding protein (SREBP) cleavage activating protein (SCAP) (36) . CT43 mutant cells were isolated as one of the cholesterol trafficking mutants from mutagenized 25RA cells (37) , containing a premature translational termination mutation near the 3'-end of the NPC1 coding sequence, and producing a non-functional, truncated NPC1 protein (38) . M19 cells were isolated from mutagenized WT CHO cells; these cells fail to respond to sterol-dependent regulation of HMG-CoA reductase and LDL receptors (39) because these cells contain a deletion mutation in site-2 protease that is required to cleave the SREBP into an active form (40) . LEX1 are mutant CHO cells isolated from WT cells. LEX1 cells exhibit defects in fusion between the late endosomes and the lysosomes, and are defective in disintegration of LDL particles labeled with fluorescent phospholipids (41) . The molecular lesion of the LEX1 cells is unknown. The LEX2 mutant cells were also isolated from WT CHO cells; they exhibit an arrested multivesicular body (MVB), and show defects in the transport of the cation independent mannose 6-phosphate receptor (CI-MPR) from the MVB back to the trans-Golgi by guest on November 19, 2017 http://www.jbc.org/ Downloaded from network (TGN). In addition, these mutant cells contain another defect in the transport of lysosomal proteins and apo-B100 in LDL to the late endosomes (42) . LEX2 cells contain a molecular lesion in the gene encoding NAD(P)Hdependent sterol dehydrogenase-like protein (NSDHL), an enzyme in the late stage of the cholesterol biosynthesis pathway. A stable transfectant of LEX2 cells that expresses an active NSDHL, called the LEX2LIB3 cell, has been reported (43) . The expression of this enzyme resulted in the correction of the cholesterol biosynthesis defect in the LEX2 cells. In LEX2LIB3 cells, the transport of CI-MPR from the MVB to the TGN is normal, and the arrested MVB disappears; however, the defective processing of endocytosed LDL to the degradative compartment remains uncorrected, suggesting that in the LEX2LIB3 cells, there remains a defect in the late stage of the endocytic pathway (43 Percoll gradient analysis -The fractionation method was performed as described previously (3) . Cells from one 150-mm dish were scraped into the homogenization buffer (0.25 M sucrose, 1 mM EDTA, 20 mM Tris, pH 7.4), and homogenized with 15 strokes using the stainless steel tissue grinder. To increase recovery, the pellet was resuspended in buffer and homogenized the second time. The combined post-nuclear supernatant from cells was loaded onto 11% Percoll and centrifuged (20, 3 H] cholesterol in each fraction was isolated and analyzed using the method of silica gel TLC (solvent system: petroleum ether : ether : acetic acid = 90:10:1) and scintillation counted according to the procedure previously employed (38, 24) . For measuring cholesterol mass, aliquots from each Percoll fraction were loaded onto the 96-well plate and processed with a Wako cholesterol assay kit that measures free cholesterol only, according to the instruction manual.
Fluorescence microscopy -Cells were grown on glass coverslips placed in six-well plates or in 60-mm dishes and processed for fluorescence microscopy studies. For DiI-LDL labeling, cells were pre-chilled on ice, and incubated with 30 µg/ml DiI-LDL in Medium D at 18 ˚C for 3 h. Cells were washed with cold PBS containing 1% BSA, then 3 times with cold PBS, followed by chase in Medium D at 37 ˚C for the indicated time periods. Coverslips were kept at 4 ˚C until the microscopic processing. The construct encoding mouse NPC1 protein fused with GFP was introduced to cells by transient transfection using the method described previously (33) . For LysoTracker labeling, LysoTracker Red DND 99 was added to the cells at final concentration of 50 nM in phenol-free DMEM at 37 ˚C for 90 min. During this period, the cells were maintained in a humidified incubator with 5% CO 2 . For immunostaining, cells were washed three times with PBS, fixed with 4% paraformaldehyde for 10 min at room temp, washed three times again, and either permeabilized with methanol (chilled at -20 C) for 1 min, or with 0.2% saponin in PBS at room temp for 10 min. When permeabilization by saponin was used, 0.1% saponin was included in all the buffers except in the washing buffer used during the last step. After three more washes, the cells were incubated with the blocking solution (10% goat serum in PBS) for 30 min at room temp, then incubated with anti-Lam2 antibody (at 200-fold dilution) present in the blocking solution for 1 h. Cells were then washed with PBS three times, treated with various secondary Alexa Fluor IgGs, then washed three more times. The coverslips were mounted with a drop of ProLong Anti-Fade media onto the glass slides before image processing. The samples were viewed and photographed in a Leica (Bannockburn, IL) TCS SP Laser scanning confocal microscope. The images were constructed and analyzed by Leica Confocal Software as described below.
Image Analysis -For each sample, quantification of staining was performed in 6 -10 photographed confocal images, each image containing 10 -20 cells. The entire cell surface of each cell on the DIC image was outlined, and the mean intensity of the fluorescent signal within each cell was calculated as a certain relative value using the Leica Confocal Software. For analyzing the fluorescence signals in the perinuclear region vs. the peripheral region, the entire cell surface and the surface of the nucleus of each cell were outlined on the DIC images. The signals located in areas within the top 1/3 toward the nucleus are considered as the signal in the perinuclear region, those covering the other 2/3 are considered as the signal in the peripheral region.
Assay to monitor late endosomal motilityThe assay employed was essentially the same as described in Lebrand and colleagues (13) . Cells were labeled with LysoTracker Red DND 99 according the method described above, then viewed under theZeiss LSM Confocal Microscope System to record time-serial images of the LysoTracker stained vesicles, at 1 sec intervals for 25 sec. For each cell type under each condition, ten images were taken per cell; a total of 300 vesicles were measured and grouped into three distance sections: a. 
RESULTS

Characteristics of various specialized CHO
cell lines employed in the current study -We used WT CHO cells, 25RA cells, and CT43 cells for most of the experiments reported in the current study. Previous work has shown that in terms of cellular cholesterol homeostasis, the WT CHO cells behave similar to human fibroblasts, while the 25RA cells behave similar to human macrophages (46, 47) . The CT43 cells are derived from the 25RA cells, and have served as a CHO cell model for the human mutant NPC1 cells. In some experiments, we also employed M19 cells, and LEX1 and LEX2 cells. M19 cells are mutant cells derived from the WT CHO cells, and are severely deficient in endoCHOL biosynthesis (39) . Thus, M19 cells behave similar to lovastatintreated WT cells. The LEX1 and LEX2 cells are also derived from the WT CHO cells. LEX1 cells contain a defect in producing mature lysosomes: they fail to transport the apoB in LDL and lysosomal marker proteins from the late endosomes to the lysosomes. LEX2 cells contain a mutation in the gene encoding NADH-dependent sterol dehydrogenase-like (NSDHL), an enzyme in the late stage of the cholesterol biosynthesis pathway (43 Fig. 2A) . In contrast, blocking endoCHOL biosynthesis confers dramatic reduction on the reesterification of LDL-CHOL in WT cells and 25RA cells ( Fig. 2B ; first 4 bars). The result of the LDL-CHOL efflux study shows that blocking endoCHOL biosynthesis moderately decreases the movement of LDL-CHOL to the PM in WT and 25RA cells ( Fig. 2C ; first 4 bars at 1 h chase time, and first 4 bars at 2 h chase time). We have previously shown that, relative to 25RA cells, CT43 cells are defective in reesterification of LDL-CHOL, and in the movement of LDL-CHOL to the PM (38) . Blocking endoCHOL biosynthesis caused a further decrease in the reesterification and in the % efflux of LDL-CHOL in CT43 cells ( Fig. 2B, C ; last two bars). Along with the results shown in Fig. 1C , these results suggest that the effect of blocking endoCHOL synthesis on LDL-CHOL movement is independent of NPC1 action. In results not shown, we found that blocking endoCHOL synthesis did not significantly alter the total uptake of [suggest that blocking endoCHOL synthesis in WT cells or in 25RA cells interferes with the normal trafficking of LDL-CHOL in a manner that mimics the trafficking defect of LDL-CHOL seen in the mutant NPC1 cells. We have previously shown that the internalization of PM-labeled CHOL to the ER for esterification partially depends on the NPC1 present in the late endosomes (38, 47) . Thus, we set out to test the possibility that blocking endoCHOL biosynthesis may also inhibit the internalization of PM-labeled CHOL in WT, 25RA, and CT43 cells. The results suggest that in cells depleted with endoCHOL, the esterification of PM-CHOL was greatly reduced ( Fig. 2D ; first 4 bars), while the % efflux of PMlabeled CHOL towards CD (as the cholesterol acceptor in medium) was significantly increased in WT and 25RA cells ( Fig. 2E ; first 4 bars). Additional results show that the CT43 cells exhibit greater CHOL efflux than the 25RA cells; treating CT43 cells with lovastatin/mevalonate caused a modest further increase in sterol efflux ( Fig. 2E ; last 2 bars). These results further support the notion that the effect of blocking endoCHOL synthesis on LDL-CHOL movement is independent of NPC1 action. Together, these results suggest that blocking endoCHOL synthesis in WT and 25RA cells interferes with the trafficking of LDL-CHOL and PM-labeled CHOL, but in a manner independent of NPC1 action. Close examination of results presented in Fig. 2 reveals that in general, the magnitude of changes caused by endoCHOL depletion is smaller in 25RA cells than in WT cells. When grown under steady state, 25RA cells exhibit a higher sterol synthesis rate and take up more LDL from the growth medium, causing these cells to contain much more cholesterol than WT cells (30) . The higher cellular cholesterol content in 25RA cells is expected to diminish/neutralize the effect created by blocking endoCHOL synthesis.
The effect of blocking endoCHOL synthesis vs. the effect of accumulating biosynthetic precursor sterols in influencing the fate of [
3 H]CL-LDL -To examine the specificity of the effect of blocking endoCHOL synthesis, we compared the uptake, hydrolysis, % reesterification, and % efflux to CD of [ 3 H]CL-LDL in WT cells, and LEX1 and LEX2 mutant cells. The result showed that the total uptake of LDL is slightly higher in WT cells than in LEX1 or LEX2 cells, but the difference is less than 30% (Fig. 3A) . The LEX1 cells only show a slight defect in CL hydrolysis, but only during early time points (Fig. 3B) . They also show a slight defect in the efflux of LDL-CHOL from the PM during earlier time points (Fig. 3D) . The reesterification rate of LDL-CHOL is actually higher in LEX1 cells than that in WT cells (Fig.  3C) . The LEX1 cells contain normal late endosomes but do not produce mature lysosomes, and are seriously defective in lysosomal degradation of the apoB protein moiety in LDL (41) ; this result suggests that upon reaching the late endosomes, the LDL-CHOL is transported from the late endosomes to the ER and/or to the PM without the need for the mature lysosomes; i.e., the lysosomes do not play a substantial role in the endocytic transport of LDL-CHOL. Results of parallel experiments revealed that in the LEX2 mutant cells, the hydrolysis of cholesteryl esters in LDL was seriously defective (Fig. 3B) . The subsequent transport of [
3 H]LDL-CHOL to the ER for reesterification, and to the PM for efflux, was also seriously defective in these cells (Fig. 3C, D) . LEX2 cells lack functional NSDHL, a key late enzyme in the cholesterol biosynthetic pathway. In a separate experiment, we compared the hydrolysis and the % efflux of [ 3 H]CL-LDL in WT, LEX1, LEX2, and LEX2LIB3 (which express a functional gene for NSDHL) cells. The results (Fig. 3E, F Fig. 4; upper panels) ; similar results were obtained when either WT or 25RA cells were used as the cell source. When the cholesterol mass was measured, the results show that blocking endoCHOL synthesis did not cause an extensive decrease in the total cholesterol content in any of the fractions in WT cells or in 25RA cells ( Fig. 4 ; lower panels). Collectively, these results suggest that, in 17 h, endoCHOL has been distributed to various subcellular organelles; however, the absolute amount of endoCHOL biosynthesized within 17 h represent small fractions of the overall cholesterol contents in these organelles. (#1-#3) , and is increased in the heavy fractions (#8-#10) (Fig. 5) . Since the differences seen between the Medium D grown cells and the Medium S grown cells are not large, we performed the two-tailed Student's t-test and obtained the following P values: for 25RA cell fractions #1-3: 0.03; for 25RA cell fractions #8-10: 0.05; for WT cell fractions #1-3: 0.01; for WT cell fraction #8-10: 0.03. We consider a p-value of 0.05 or less to be significant. Thus, this analysis shows that the differences seen between the values in Medium D and Medium S are statistically significant. The same finding was obtained in a separate experiment, when the WT and 25RA cells were pulsed under the same condition, but chased at 37 ˚C for 1 h only (data not shown). These results suggest that in lovastatin-treated WT or 25RA cells, the exit of LDL-CHOL from the late endosomes is partially delayed.
DiI-LDLs are LDLs labeled with DiI, which is a lipophilic, membrane-impermeant fluorescent dye (1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine). Previous work showed that DiI-LDLs undergo the same endocytic, degradative process as normal, unlabeled LDLs; afterwards, DiI remain trapped within the subcellular organelles that deposited/degraded the DiI-LDL (49) . To visualize the trafficking of LDL in intact cells by microscopic means, we labeled 25RA cells grown in Medium D or in Medium S at 18 ˚C with DiI-LDL, chased the cells at 37 ˚C for 0, 30, or 120 min, and observed and recorded them under fluorescence microscopy. DiI-LDL initially showed the peripheral distribution at 0 min chase, suggesting that it may accumulate in the prelysosomal compartment at 18 ˚C (Fig. 6A) ; at 30 min chase, much of the fluorescence became perinuclear (Fig. 6B) . The relative signal intensities were analyzed by performing image analysis, and are tabulated in the right panels of for 60 min (data not shown), or for 120 min (Fig.  6C ). This result suggests that the endocytic processing of DiI-LDL is sluggish in cells deprived of endoCHOL synthesis. These results together with the result shown in Fig. 5 Thus, in cells deprived of endoCHOL synthesis, the NPC1-GFP remains mainly in the late endosomes/lysosomes, We did note that, in the 25RA and WT cells grown in Medium D, both the NPC1-GFP and the Lamp-2 signals mainly localized in the perinuclear region, which is characteristic of the normal cellular distribution pattern of the late endosomes/lysosomes. In contrast, in 25RA cells grown in Medium S, a significant percentage of the NPC1-GFP/Lamp2 signals were shifted to the peripheral region. Similarly, in M19 cells grown in Medium D, the majority of the NPC1-GFP/Lamp2 signal was found to be at the peripheral region, in contrast to the perinuclear distribution found in WT cells grown in the same medium. The perinuclear/peripheral distribution of the Lamp-2 signal, in various cells under Medium D or Medium S conditions, are measured semiquantitatively, and are presented in Fig. 7B . The results show that deprivation of endoCHOL synthesis alters the cellular distribution of the late endosomes/lysosomes from a mainly perinuclear pattern to a mainly peripheral pattern. In results not shown, we stained live cells with the fluorescent dye LysoTracker, which specifically stains late endosomes and lysosomes, to monitor the effect of blocking endoCHOL synthesis on cellular distribution of the late endosomes/lysosomes, and have obtained the same results as shown in Fig. 7 .
We next performed a time course study, to monitor the change in late endo/lysosomal localization pattern in WT cells after adding lovastatin/mevalonate. The result (Fig. 8A) shows that adding lovastatin/mevalonate for 2 h or longer produces significant alterations in the late endo/lysosomal localization pattern, in time dependent manner. We also performed a time course study on the effect of adding LDL to revert the abnormal late endo/lysosomal localization pattern caused by lovastatin/mevalonate. The result (Fig. 8B) shows that adding LDL for 2 h or longer significantly reverts the abnormal late endo/lysosomal localization pattern, in a timedependent manner. Together, these results support the interpretation that the effect of lovastatin/mevalonate on late endo/lysosomal function occurs within a couple of hours. Since adding LDL can reverse the effect of lovastatin/mevalonate, the effect of lovastatin/mevalonate is to deplete endoCHOL synthesis, not to deplete other mevalonate derived, non-sterol metabolite(s). Earlier, we have shown that adding lovastatin/mevalonate significantly reduces the cells' ability to mediate the efflux of LDL-derived CHOL (Fig. 1) . We tested if adding LDL or adding cholesterol for longer time (4 h) can neutralize the effect of lovastatin/mevalonate. The result (Fig. 9) shows that cells grown in CHOL. These results further support the interpretation that the effect of adding lovastatin/mevalonate is mainly to deplete endoCHOL.
Motility of the late endosomes/lysosomes in cells deprived of endoCHOL synthesis -In NPClike cells with abnormal cholesterol accumulation, the late endosomes exhibit a peripheral location pattern, and become relatively immobile (13) . Since we have shown that cells deprived of endoCHOL synthesis exhibit a peripheral late endosomes/lysosomes location pattern, the mobility of the late endosomes/lysosomes in these cells may be reduced. To test this possibility, we stained live WT cells grown under various conditions with LysoTracker, and monitored the stained particles under time-lapse video microscopy. As expected, numerous LysoTrackerstained vesicles and tubules were present, and they exhibited linear, long distance, bi-directional, saltatory motion between the cell periphery and the perinuclear region. The movement patterns of the LysoTracker-stained elements that we observed were very similar to what had previously been described as the movement patterns of the late endocytic compartment in HeLa cells by Lebrand and colleagues (13) . In experiments not shown, we labeled the late endosomal compartment by expressing the NPC1-GFP in WT cells, and observed essentially the same movement patterns as those of the LysoTracker-labeled vesicles and tubules (results not shown). We used the method described by Lebrand and colleagues to estimate the motility of the LysoTracker-stained particles; the distances between the initial position (marked in green) and the final position (marked in red) of each stained vesicle over a total time period of 25 sec were recorded using the SLM 5 Image Browser; the representative images are shown in Fig. 10A . We quantitated the labeled vesicular particles that traveled more than 1.5 µm in 25 sec in each cell, and treated them as the mobile elements. The results are shown in Fig.  10B , right section. We also recorded those particles that exhibited Brownian-type motion only (i.e., those that remained confined within 0.75 µm of their initial position after 25 sec). The results are shown in Fig. 10B , left section. For those particles that traveled between 0.75 and 1.5 µm, it is difficult to determine whether they are due to long distance, bidirectional movement, or due to Brownian-type motion (13) . They are quantitated separately, and presented as the middle section in Fig. 10B . The changes of numbers in the slow-moving particles in response to cellular cholesterol content are less reliable, because of the large and nonmobile background values. The quantitations of these slower moving particles (left section and middle section) are also recorded. The results shown in right section of Fig. 10B , reporting the fast moving particles, demonstrate that cells grown in Medium D contained higher numbers of mobile endosomal elements than those grown in Medium A (Medium A contains 10% fetal bovine serum, and is rich in cholesterol bound to lipoproteins); this number was considerably decreased when the cells were grown in Medium S. Additional results show that the inhibitory effect by lovastatin/mevalonate is reversible, since adding LDL to these cells caused them to increase the number of mobile elements in a time-dependent manner. In experiments not shown, similar observations were made when 25RA cells were used to perform the same type of experiments, though the magnitude of the changes observed in the 25RA cells was relatively smaller than that observed in the WT cells. Since the differences in mobility observed were not large, we performed statistical analyses of the data, using one-way ANOVA analysis. For simplicity, we combined the Medium S plus LDL for 2 hr data and the 12 hr data as a single group. The results show that for the <0.75 µm vesicles, the P-value for the differences seen between Media A, D, S, and S plus LDL grown cells is below 10-10; for the 0.75-1.5 µm vesicles, the P-value is below 10-5; for the >1.5 µm vesicles, the P-value is below 10-9. Thus, for the short, intermediate, and long distance moving vesicles, the differences in mobility observed between Media A, D, S, and S plus LDL grown cells are all statistically significant.
Rab proteins, a family of small GTPases involved in various membrane trafficking events, in part control the endosomal motility (50, 34) . In mutant NPC1 cells, overexpressing the wild-type Rab9 causes significant dissipation of the abnormal cholesterol accumulation (50, 34) . It is possible that overexpressing Rab9 may increase the endosomal motility in cells deprived of endoCHOL synthesis. To test this possibility, we overexpressed the Rab9-YFP fusion protein by Fig. 10C; left panel) show that overexpressing Rab9-YFP does not rescue the inhibitory effect of endoCHOL deprivation on endosomal motility. The result of the control experiment shows that overexpressing Rab9-YFP in the mutant NPC1 cells (i.e., CT43 cells) does increase the endosomal mobility in these cells grown under cholesterol-loaded conditions ( Fig. 10C; right  panel) .We performed statistical analyses of the data shown in Fig. 10C , using Student's t-test. The results show that for the WT cells, the mobility difference with or without Rab 9 overexpression is statistically insignificant (the Pvalues are 0.16 for the d<0.75 µm, 0.72 for the 0.75-1.5 µm, and 0.06 for the d>1.5 µm vesicles). In contrast, for the CT43 cells, the mobility difference with or without Rab9 is statistically significant (P-values are 0.004 for the d<0.75 µm, 0.02 for the 0.75-1.5 µm, and 0.003 for the d>1.5 µm vesicles).
DISCUSSION
Late endosomes are important organelles involved in various membrane trafficking events. Previous studies have demonstrated effects of cholesterol at various stages of endocytosis (51, 52, 43, (53) (54) (55) (56) . However, these studies did not specifically demonstrate whether depleting cholesterol content would affect the motility and cholesterol trafficking activities of the late endosomes. Previous studies have demonstrated that newly synthesized endoCHOL is rapidly transported to the caveolae/lipid raft microdomain of the PM within 10 to 20 min (18) (19) (20) (21) . At the PM, endoCHOL may recycle rapidly (within minutes) between the PM and the recycling endosomes (23) . In mutant NPC1 cells, 8 h or longer after its initial synthesis, a certain portion of endoCHOL is significantly trapped within the late endosomes; the degree of entrapment occurs in a cell-typedependent manner (47) . These studies implicate that endoCHOL moves to the late endosomal compartment within 8 h after its synthesis. In our current work, we show that depleting endogenous cholesterol synthesis for 2-3 h causes the late endo/lysosomes to begin to malfunction. Feeding cells with LDL can rescue the malfunction of the late endo/lysosomes caused by endoCHOL depletion. Thus, based on functional criteria, within 2 to 3 h after its biosynthesis, endoCHOL reaches the late endo/lysosomal compartment, and plays important role(s) in controlling the motility and its cholesterol trafficking activities. In Fig. 11 , we draw a model to highlight the new information regarding the trafficking route of endoCHOL, contrasting the trafficking route of LDL-CHOL in mammalian cells.
Our results imply that a small but significant reduction in endosomal motility can cause them to mislocalize within the cells. How can a small change seen in endosomal motility significantly impact their functions? The endosomal motility measurement was done in 25 sec. In this period, only 10% of the late endo/lysosomes are mobile; the rest are not mobile and only exhibit Brownian motions. Within a few minutes, all of the late endosomes are engaged in long-distance, bidirectional movements (13, 14) . The kinetic experiments described in our current work suggest the following scenario: the decrease in endosomal motility alters the localization pattern of the late endosomes (from being mostly perinuclear to being mostly peripheral), and adversely impacts the functions of the late endo/lysosomes in terms of their cholesterol trafficking activities. This interpretation is consistent with the previous results by Lebrand and colleagues (13) , who showed that abnormal cholesterol loading in the late endosomes/lysosomes of NPC-like cells causes a small but significant decrease in endosomal motility and mislocalization. Lebrand and colleagues proposed that diminishing the late endosomal motility is the major cause for slowing down the ability of the late endosomes in membrane trafficking. In our current work, we show that depleting the cellular cholesterol content can also causes a small but significant decrease in endosomal motility, and in intracellular cholesterol trafficking activities. Thus, our current results support the concept that late endosomal motility plays a key role in controlling endosome-mediated cholesterol trafficking events.
There are two cholesterol related causes for reducing the motility of the late endosomes in cells. The first cause is the accumulation of endosomal LDL-CHOL. This can occur through mutations in NPC1 or NPC2, through Lamp1/Lamp2 deficiency, or by treating cells with various drugs (reviewed in (8)). Late endosomes contain Rab7 and Rab9. Rab7 interacts more with earlier endosomes and lysosomes; Rab9 interacts more with the trans-Golgi (reviewed in (15) ). Cholesterol accumulation in late endosomes leads to the inhibition of Rab7, which in turn reduces the late endosomes' motility (13); overexpressing Rab9 can overcome the cholesterol accumulation defect in mutant NPC1 cells (50, 34) . A second cholesterol-related cause of reduced endosomal motility is endoCHOL deficiency, as demonstrated in the current manuscript. We show that overexpressing the Rab9-YFP does not overcome the reduced endosomal motility caused by endoCHOL deficiency. Therefore, the effect of endoCHOL deficiency on endosomal motility may not be related to the function of Rab9. We also show that depleting endoCHOL in CT43 cells, i.e., cells lacking a functional NPC1, causes further decrease in cholesterol trafficking activities in these cells (Fig. 2) . Thus, the effect of endoCHOL depletion on endosomal motility is probably unrelated to NPC1. Hao and colleagues have shown that cellular cholesterol content modulates the membrane properties of the late endosomes (56). Thus, it is possible that endoCHOL may be required to maintain the proper lipid composition and/or the shape of the limiting membranes of the late endosomes, such that the late endosomes can interact properly with the microtubules, to participate in various membrane trafficking activities. Other possibilities cannot be excluded at present.
Our current work shows that in cells lacking endoCHOL synthesis, LDL-CHOL transiently accumulates in the late endosomes/lysosomes. However, incubating the endoCHOL depleted cells with LDL for 4 h can rescue the abnormality of the late endo/lysosomes. We rationalize these findings based on the fact that the initial fates and the trafficking routes for LDL-CHOL and endoCHOL differ from each other. Within 2 to 3 h after synthesis, endoCHOL may constitute a small but important cholesterol pool that may rapidly travel through certain membrane microdomain(s) within the endosomal system; this microdomain is not immediately accessible to LDL-CHOL. This interpretation is supported by the fact that in cells depleted with endoCHOL synthesis, the pool of newly synthesized cholesterol becomes markedly deficient in various cellular organelles, although their total cholesterol pool does not significantly decrease (Fig. 4) . The late endo/lysosomes lacking endoCHOL are functionally deficient in distributing/sorting LDL-CHOL, and become relatively immobile. The impairment in late endosomal motility can be rescued by adding LDL, but only in a timedependent manner ( Fig. 8B; 9, 10 ), suggesting that with time, LDL-CHOL can eventually reach the membrane microdomain deficient in endoCHOL.
These observations suggest that endoCHOL and LDL-CHOL may exist as two different, nonequilibrating pools within the same late endosomes. This hypothesis is consistent with the fact that late endosomes are multivesicular. In vitro studies showed that upon repeated freezing and thawing of the purified late endosomes, the limiting membranes can be separated from the internal membranes, and exhibit distinct protein and lipid compositions (57) . In the future, it would be interesting to examine whether these membrane fractions differ in their cholesterol contents. Since blocking endoCHOL synthesis leads to a significant decrease in endoCHOL pool in various cellular fractions, endoCHOL may also affect the functional/structural integrity of other endosomal compartment(s). These possibilities can also be explored in the future.
We also compared the fate of [ 3 H]CL-LDL in WT cells and LEX1 cells, and showed that late endosomes, but not lysosomes, play important roles in the trafficking and the distribution of LDL-CHOL. Other results showed that while the endosomal cholesteryl ester hydrolysis step is normal in cells lacking endoCHOL synthesis, this step is severely defective in LEX2 cells that accumulate biosynthetic precursor sterols (Fig. 3) . In NPC1 cells, the accumulation of cholesterol does not significantly inhibit the hydrolysis of [ 3 H]cholesteryl esters in LDL (22, 38) . Thus, the accumulation of biosynthetic precursor sterols in endocytic vesicles may cause undesirable effects in a way that is distinct from the effect caused by accumulation of cholesterol. This interpretation is consistent with the work of Heese-Peck et al. (54) who showed that in budding yeast, sterols with different structural types affect the endocytic pathway in different manners.
Although we have only used cells derived from CHO cells for our current study, we believe that our findings will be relevant to other cell types, because various mammalian cells continue to synthesize endoCHOL despite the fact that they also receive LDL externally (58) . Our findings may be most relevant to neuronal and glial cells in the brain, because cells in the central nervous system receive cholesterol mainly from de novo synthesis, not from LDL (59). Fig. 1. A 3 H]CL-LDL were analyzed according to the procedures described previously (3) . Error bars indicate sizes of 1 S.E. Results are representative of two independent experiments. C, Effect of inhibiting endoCHOL synthesis on cellular NPC1 and NPC2 protein levels. In parallel with the pulse and chase experiment described above, after incubation in Medium D for 36 h (lane 1), or in Medium D for 20 h, followed by Medium S for 16 h (lane 2), cells were lysed with 1% NP-40. The lysates were analyzed for NPC1 or NPC2 by Western blotting, using rabbit anti-hamster NPC1 polyclonal antibodies DM105 (top bands; 0.8 µg IgG /ml), or rabbit anti-NPC2 polyclonal antisera (middle bands; 1:2000 dilution), or mouse anti-beta actin (bottom bands; 1 to 50000 dilution) as indicated. 400 µg, 50 µg, and 50 µg of the cell lysates were used for Western blot analyses of NPC1, NPC2, and beta-actin, respectively. The results were analyzed by densitometry, and were reported by using values in cells grown in Medium D as 100%. Results are representative of two independent experiments. WT and CT43 Cells were grown in Medium S or Medium A, respectively, on eight-well chambered cover glass for 2 days, then were transfected with Rab9-YFP (indicated as Rab9 (+)), or were mock-transfected (indicated as Rab9 (-)). For WT cells, 24 h after transfection, cells were grown in Medium D for 36 h, switched to Medium S for 12 h, then labeled with LysoTracker. For CT43 cells, 24 h after transfection, cells were grown in Medium A for two days, then labeled with LysoTracker. The method used for motility study was the same as described in A-B. Results shown are representative of two separate experiments. Fig. 11 . Model describing the early trafficking route of newly synthesized endoCHOL, contrasting the trafficking route of LDL-CHOL. Light yellow circles represent cholesterol molecules. This model is an extension and revision of the earlier models drawn in (3, 24) . See "Introduction" and "Discussion" for details. Abbreviations used in the Fig.: ACAT1, acyl-coenzyme A: cholesterol acyltransferase 1; AL, acid lipase; CEH, cholesteryl ester hydrolase; EE, early endosomes; ERC, endocytic recycling compartment; LE, late endosomes; PM, plasma membrane; SCAP, SREBP cleavage activating protein; SREBP, sterol
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